Your session is about to expire
← Back to Search
Pembrolizumab for Adrenocortical Cancer
Study Summary
This trial is testing a new cancer treatment called pembrolizumab. Researchers want to learn what effects, both good and bad, this immunotherapy has on patients and their cancer.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been diagnosed with advanced ACC that cannot be removed with surgery or treated effectively with local therapies.You have a disease that can be measured using specific guidelines.You have taken a specific type of medication in the last 4 weeks or have not fully recovered from side effects of a medication taken more than 4 weeks ago.You have cancer that has spread to your brain or spinal cord.You have given a sample of tissue for testing the PD-L1 biomarker.You have a current infection that needs medication to treat.You have been diagnosed with Human Immunodeficiency Virus (HIV).You currently have active Hepatitis B or Hepatitis C.You should be able to perform daily activities without any major limitations or only have slight limitations.You have a weakened immune system or are taking strong medications that weaken the immune system.You have received chemotherapy or targeted therapy within 2 weeks before the study starts and have not fully recovered from any side effects.You have another type of cancer that is getting worse or needs treatment other than for certain types of skin cancer or early-stage cervical cancer that has been treated.You have a serious autoimmune disease or are currently receiving treatment for an autoimmune condition.You have a history of lung problems that needed steroids or have ongoing lung inflammation.You have received treatment with certain types of medications that affect the immune system.
- Group 1: Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what medical conditions is Pembrolizumab most often prescribed?
"Pembrolizumab is an immunotherapy medication used to treat cancer. It can also help patients with conditions like microsatellite instability high and unresectable melanoma who have seen disease progression after chemotherapy."
Are there any available spots for people in this clinical trial?
"This study has closed recruitment. The clinical trial was first posted on February 1st, 2016 and was last edited on March 3rd, 2022. However, there are presently 2551 trials actively recruiting patients with adrenocortical carcinoma and 1000 studies for Pembrolizumab admitting patients."
What are the risks associated with Pembrolizumab?
"Pembrolizumab's safety is supported by phase 2 data, but since there is a lack of efficacy data, it received a score of 2."
What other treatments has Pembrolizumab been tested against in scientific trials?
"Pembrolizumab is being trialed in 1000 active studies, with 122 of those being Phase 3 trials. The majority of these are based in Houston, Texas; however, there are 36053 locations running Pembrolizumab trials globally."
How many individuals are being given the opportunity to participate in this research project?
"This particular clinical trial is not currently looking for new participants. However, there are 2551 other trials related to adrenocortical carcinoma and 1000 trials related to Pembrolizumab that are actively recruiting patients."
Share this study with friends
Copy Link
Messenger